Literature DB >> 9831329

Cyclooxygenase-2 as a therapeutic target.

J A Mitchell1, T W Evans.   

Abstract

Cyclooxygenase (COX)-2 is the predominant COX isoform present at sites of inflammation, and produces prostaglandins (PG) that cause swelling and pain. However, in situations where the release of protective PGs by COX-1 has been lost, the induction of COX-2 may compensate and reduce inflammatory responses. This is particularly likely in large blood vessels, where, under physiological conditions, the release of prostacyclin by COX-1, present in the endothelium, is an important component of cardiovascular homeostasis. We, and others, have recently shown that COX-2 can be induced by proinflammatory cytokines in human blood vessels, and also in human airway cells. Moreover, recent data from our group have suggested that in these structures, COX-2 is anti-inflammatory at the level of cellular proliferation, adhesion receptor expression, and cytokine release.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9831329     DOI: 10.1007/s000110050287

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  17 in total

Review 1.  Present status and strategy of NSAIDs-induced small bowel injury.

Authors:  Kazuhide Higuchi; Eiji Umegaki; Toshio Watanabe; Yukiko Yoda; Eijiro Morita; Mitsuyuki Murano; Satoshi Tokioka; Tetsuo Arakawa
Journal:  J Gastroenterol       Date:  2009-07-01       Impact factor: 7.527

2.  Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor alpha-dependent repression of cyclin D1.

Authors:  Valerie Y Ng; Christophe Morisseau; John R Falck; Bruce D Hammock; Deanna L Kroetz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-08-17       Impact factor: 8.311

Review 3.  Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor.

Authors:  N M Davies; A J McLachlan; R O Day; K M Williams
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 4.  Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy.

Authors:  J A Mitchell; T D Warner
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

Review 5.  Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense.

Authors:  John L Wallace; Pallavi R Devchand
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

Review 6.  Future directions in thrombolysis.

Authors:  J T Willerson; P Zoldhelyi
Journal:  Clin Cardiol       Date:  1999-08       Impact factor: 2.882

Review 7.  Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives.

Authors:  F Halter; A S Tarnawski; A Schmassmann; B M Peskar
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

8.  Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression.

Authors:  S Aggarwal; N Taneja; L Lin; M B Orringer; A Rehemtulla; D G Beer
Journal:  Neoplasia       Date:  2000 Jul-Aug       Impact factor: 5.715

Review 9.  Capsule endoscopic diagnosis of nonsteroidal antiinflammatory drug-induced enteropathy.

Authors:  Laurence Maiden
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

10.  Role of mast cells and protease-activated receptor-2 in cyclooxygenase-2 expression in urothelial cells.

Authors:  Zun-Yi Wang; Peiqing Wang; Dale E Bjorling
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-08-12       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.